We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Bayer Acquires Rights to Viral Diagnostics

By HospiMedica staff writers
Posted on 28 Mar 2001
Bayer Diagnostics (Tarrytown, NY, USA) and Innogenetics N.V. More...
(Ghent, Belgium), an international biomedical company, have announced a series of agreements in the field of in vitro nucleic acid based viral diagnostics.

Under these agreements, Bayer will acquire the exclusive worldwide rights for the sale and marketing of Innogenetics' LiPA HIV and LiPA HCV (hepatitis C virus) nucleic acid based products and their future generations. These products include a leading genotyping test for HCV and an extensive line of HIV drug resistance assays. Innogenetics will manufacture the existing products and develop future generations.

In return, Bayer will make a payment to Innogenetics of 10.4 million Euro, a future milestone payment, and R&D funding for the next five years. Bayer will also pay for the supply of the products and will make an equity investment of 10 million Euro in Innogenetics. "These high-quality products from Innogenetics are a perfect complement to our developing portfolio of nucleic acid based tests,” said Peter Knueppel, head of nucleic acid diagnostics at Bayer.



Related Links:
Bayer Diagnostics
Innogenetics

Gold Member
Neonatal Heel Incision Device
Tenderfoot
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Resorbable Bovine Collagen Membrane
GenDerm
Syringe Pump
SP50 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Medical Imaging

view channel
Images from patient T1, who had menstrual cycle–dependent right shoulder pain. (A) Maximum-intensity-projection images show abnormal findings for right diaphragm (arrowhead), bilateral round ligaments, peritoneum around bilateral ovaries, and left fallopian tube. Combined PET/MRI show hyperintense lesion with focal uptake inferior of right diaphragm, indicative of endometriosis (arrowhead, B). Confirmatory laparoscopy demonstrated extensive pelvic disease and implants of right diaphragm (C) that stained intensely positive for FAP (D).  (Image Credit: Schindler P, Brandt J, Bobe S, et al. Initial results of FAPI PET/MRI to assess the extent of endometriosis. J Nucl Med. 2026;67(8):1232–1238. doi:10.2967/jnumed.125.271376)

Targeted PET/MRI Improves Detection and Preoperative Mapping of Endometriosis

Endometriosis is a chronic inflammatory condition in which endometrial-like tissue grows outside the uterus, causing pelvic pain, infertility, and reduced quality of life. Conventional imaging can underestimate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.